U.S. Electronic Equipment and Components Stock News

NasdaqGS:DHC
NasdaqGS:DHCHealth Care REITs

A Look At Diversified Healthcare Trust (DHC) Valuation After Earnings Reveal Narrower Net Loss

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

Assessing Mercury Systems (MRCY) Valuation After Growth Update And Rising Defense Opportunities

Mercury Systems (MRCY) recently reported year over year growth in bookings, revenue, adjusted EBITDA, and backlog, supported by faster customer deliveries and factory automation investments, and outlined new opportunities linked to the defense budget. See our latest analysis for Mercury Systems. At a share price of US$89.03, Mercury Systems has seen a 33.28% 90 day share price return and a very large 100.47% 1 year total shareholder return, suggesting recent momentum has been strong as...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Assessing Vera Therapeutics (VERA) Valuation After FDA Priority Review And Phase 3 IgAN Success

Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness. See our latest analysis for Vera Therapeutics. Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of...
NYSE:PNFP
NYSE:PNFPBanks

Pinnacle Financial Partners (PNFP) Is Down 10.1% After Inflation, Credit Worries Hit Regional Banks – Has The Bull Case Changed?

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...
NYSE:FOUR
NYSE:FOURDiversified Financial

A Look At Shift4 Payments (FOUR) Valuation After Weak Guidance And Leadership Change

Shift4 Payments (FOUR) is back in focus after a sharp post earnings sell off, weaker forward guidance, and the resignation of Executive Chairman Jared Isaacman. Shares have slid to multi year lows despite ongoing international expansion. See our latest analysis for Shift4 Payments. The weak outlook and leadership change have come on top of a sharp reset in expectations, with a 1 day share price return of 9.0% decline and a 1 year total shareholder return of 55.4% decline, pointing to fading...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

How Robust 2026 Guidance And Backlog Conversion At Sterling Infrastructure (STRL) Has Changed Its Investment Story

Sterling Infrastructure, Inc. has already reported its fourth-quarter and full-year 2025 results, with Q4 sales of US$755.61 million versus US$498.83 million a year earlier, and full-year 2025 sales of US$2.49 billion and net income of US$290.15 million. Alongside these results, management issued 2026 guidance calling for US$3.05–3.20 billion in revenue and US$11.65–12.25 in diluted EPS, signaling confidence in converting a much larger backlog and recent acquisitions into earnings. We will...
NYSE:BSM
NYSE:BSMOil and Gas

Assessing Black Stone Minerals (BSM) Valuation After Strong 2025 Results And New 2026 Production Guidance

Why Black Stone Minerals Is In Focus After Its Latest Earnings Release Black Stone Minerals (BSM) is back on investors’ radar after releasing fourth quarter and full year 2025 results that highlighted higher revenue and net income, alongside fresh 2026 production guidance and detailed 2025 operating metrics. See our latest analysis for Black Stone Minerals. The earnings release and 2026 production guidance arrived after a steady run, with Black Stone Minerals’ share price showing an 11.77%...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

A Look At Palantir Technologies (PLTR) Valuation After Recent Analyst Upgrades And AI Optimism

Recent analyst upgrades on Palantir Technologies (PLTR), led by UBS and Rosenblatt, have refocused attention on the company’s role in artificial intelligence and data analytics, particularly following a sharp pullback in the share price. See our latest analysis for Palantir Technologies. Those upgrades and AI partnerships come after a sharp reset in sentiment, with a 30 day share price return of 6.41% and a 90 day share price return of 18.09% contrasted with a very large 3 year total...
NasdaqGS:TSEM
NasdaqGS:TSEMSemiconductor

Assessing Tower Semiconductor (NasdaqGS:TSEM) Valuation After New AI And Photonics Partnerships

Market reaction to new AI and photonics partnerships Tower Semiconductor (TSEM) has drawn fresh attention after a series of AI focused photonics partnerships, including Salience Labs, Xanadu, and Scintil Photonics, coincided with a 3.68% share price drop on 26 February. See our latest analysis for Tower Semiconductor. These AI and photonics deals come after a strong run for Tower Semiconductor, with a 90 day share price return of 11.63% and a 1 year total shareholder return of 193.81%...
NasdaqGS:KALU
NasdaqGS:KALUMetals and Mining

Is Kaiser Aluminum (KALU) Still Attractive After A 90% One-Year Share Price Surge?

If you are wondering whether Kaiser Aluminum's current share price lines up with its underlying worth, this article walks through the key signals you will want to weigh. The stock last closed at US$130.14, with returns of 0.9% over 7 days, 6.1% over 30 days, 8.2% year to date, 90.5% over 1 year, 74.0% over 3 years, and 36.6% over 5 years. This performance sets an important backdrop for any value check. Recent coverage around Kaiser Aluminum has focused on how investors view its role within...
NYSE:PSA
NYSE:PSASpecialized REITs

Public Storage Headquarters Shift And Data Partnership Reframe Growth Story

Public Storage (NYSE:PSA) is relocating its corporate headquarters from California to North Texas, alongside a leadership transition. The company has also entered a data science partnership with Welltower to support capital allocation and operational analytics. Both moves mark a shift in how Public Storage organizes its operations and uses data to run its self storage platform. For investors watching NYSE:PSA, these corporate decisions sit alongside a share price of $307.06 and a value...
NYSE:AKR
NYSE:AKRRetail REITs

Is Acadia Realty Trust (AKR) Pricing Reflect Its Mixed Returns And DCF Implied Upside

If you are looking at Acadia Realty Trust and wondering whether the current share price gives you good value, this article will walk through what the numbers are actually saying. The stock last closed at US$20.92, with returns of 3.2% over 7 days, 4.5% over 30 days, 1.4% year to date, a 5.6% decline over 1 year, 62.7% over 3 years and 30.0% over 5 years. Together, these figures provide a wide mix of recent and longer term outcomes to think about. Recent moves in Acadia Realty Trust's share...
NYSE:PRM
NYSE:PRMChemicals

Perimeter Solutions Balances Sauget Setbacks With Acquisition And Contract Shift

Perimeter Solutions (NYSE:PRM) is dealing with operational and safety issues at its Sauget P2S5 facility that have led to reduced production and ongoing litigation as it seeks to take control of the site. The company has recently closed a sizeable acquisition while shifting more of its portfolio toward fixed and recurring contracts to support more consistent earnings. These developments affect a key production asset and the structure of Perimeter Solutions' revenue, with potential...
NYSE:UGI
NYSE:UGIGas Utilities

How Investors May Respond To UGI (UGI) Distribution Rate Hike Suspension And Gas Cost Increases

In recent weeks, UGI Utilities has begun additional natural gas system upgrades in Lancaster and implemented higher purchased gas cost rates, while its proposal for a US$99.40 million annual distribution rate increase has been temporarily suspended by the Pennsylvania Public Utility Commission for further review. Together, these infrastructure investments, customer bill impacts, and regulatory oversight highlight how UGI’s earnings profile is closely tied to state-level rate decisions and...
NYSE:IDA
NYSE:IDAElectric Utilities

Will Strong 2025 Earnings and New 2026 EPS Guidance Change IDACORP's (IDA) Narrative?

IDACORP, Inc. recently reported its full-year 2025 results, with sales of US$1.81 billion, revenue of US$1.81 billion, and net income rising to US$323.47 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. At the same time, the company issued 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, highlighting management’s expectations while signaling limited use of additional tax credits under Idaho’s regulatory...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Regeneron News Highlights Rare Disease Focus And Valuation Gap

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis, a chronic nasal disease. The FDA also accepted garetosmab for Priority Review for treating fibrodysplasia ossificans progressiva, a rare and serious genetic disorder. For you as an investor, these decisions highlight where Regeneron focuses its efforts: targeted biologic therapies in areas with limited existing options. Dupixent already sits at the center...
NasdaqGS:SIRI
NasdaqGS:SIRIMedia

Is It Time To Reassess Sirius XM (SIRI) After Recent Share Price Weakness?

If you are wondering whether Sirius XM Holdings is still priced fairly after everything that has happened to the stock, this article walks through what the current share price could mean for long term investors. The stock recently closed at US$21.96, with returns of 4.3% over 7 days and 7.9% over 30 days, while the 1 year return sits at a 4.5% decline and the 3 and 5 year returns are 42.3% and 55.6% declines. Those mixed returns have arrived against a backdrop of ongoing product, content and...
NasdaqGS:SONO
NasdaqGS:SONOConsumer Durables

Assessing Sonos (SONO) Valuation After New Agentic AI Initiative With EXL And AWS

Sonos (SONO) has become a talking point after EXL announced a transformation initiative with Sonos and Amazon Web Services to deploy agentic AI within Sonos IT service management workflows, targeting efficiency, operational intelligence, and risk mitigation. See our latest analysis for Sonos. The latest AI initiative sits against a mixed share price backdrop, with Sonos trading at US$15.40 and showing a 7.3% 1 month share price return but a 17% 3 month share price decline. The 1 year total...
NYSE:MO
NYSE:MOTobacco

Is It Time To Reassess Altria Group (MO) After Strong Share Price Gains?

If you are wondering whether Altria Group's share price still lines up with its underlying value, this article walks through the key numbers that matter before you make any big calls. Altria Group recently closed at US$69.04, with returns of 2.2% over 7 days, 11.4% over 30 days, 20.5% year to date, 32.5% over 1 year, 88.4% over 3 years and 125.9% over 5 years. These figures raise fair questions about how the current price compares to estimated fair value. Recent news coverage has focused on...
NYSE:RYN
NYSE:RYNSpecialized REITs

Is Rayonier (RYN) Now Offering Value After Recent Share Price Weakness

If you are wondering whether Rayonier's current share price reflects its underlying value, this article will walk through what the numbers are actually saying. At a last close of US$21.49, Rayonier's shareholders have seen a 5.2% decline over the past week and a 5.5% decline over 30 days. The stock is also lower over 1 year, 3 years, and 5 years. These recent returns have put more attention on how Rayonier is being valued and what expectations are built into the current price. With the share...
NYSE:UBER
NYSE:UBERTransportation

A Look At Uber Technologies (UBER) Valuation After Uber Air And Robotaxi Expansion

Uber Technologies (UBER) has moved beyond traditional ride hailing with two headline launches: Uber Air with Joby Aviation in Dubai and Uber Autonomous Solutions for commercializing robotaxis across multiple markets. See our latest analysis for Uber Technologies. Despite a stream of announcements around Uber Air, autonomous charging hubs, and the new Uber Autonomous Solutions platform, momentum in the share price has cooled, with a 30 day share price return of 5.78% decline and a year to date...
NasdaqGS:NMRK
NasdaqGS:NMRKReal Estate

Is It Time To Reassess Newmark Group (NMRK) After Recent Share Price Weakness?

If you are wondering whether Newmark Group's share price reflects its underlying worth today, you are not alone. This article is set up to help you frame that question clearly. The stock recently closed at US$14.52, with returns of a 3.8% decline over 7 days, 18.6% decline over 30 days, 14.4% decline year to date and 0.2% decline over the past year, while the 3 year and 5 year returns sit at 89.2% and 50.1% respectively. These moves have put valuation back in focus for Newmark Group...
NasdaqGS:SSNC
NasdaqGS:SSNCProfessional Services

Assessing SS&C Technologies (SSNC) After Recent Share Price Weakness And DCF Upside Potential

If you are wondering whether SS&C Technologies Holdings is offering fair value at its current price, or if the market is mispricing it, this article walks through the key numbers that matter for you as a shareholder or potential investor. The stock last closed at US$75.29, with a recent 5.5% gain over 7 days sitting against a 12.2% decline year to date and a 14.4% decline over the past year. The 3 year and 5 year returns are 31.4% and 21.6% respectively. These mixed returns sit alongside an...